U.S., July 24 -- ClinicalTrials.gov registry received information related to the study (NCT07723560) titled 'Study of Surgical Practices in Hemophilia A Patients Treated With Efanesoctocog Alfa (Altuvoct(R))' on July 20.
Brief Summary: Hemophilia A is an inherited bleeding disorder caused by the absence or deficiency of coagulation factor VIII. The perioperative management of individuals with hemophilia A involves replacement therapies, typically through bolus or continuous infusions of Factor VIII, to ensure effective hemostatic control during surgery.
Efanesoctocog alfa represents a significant advance in treatment. It is a highly engineered, VWF-independent, recombinant FVIII fusion molecule with an ultra-long half-life of 47 hours in ...